

F Cardoso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5598404/publications.pdf>

Version: 2024-02-01

176
papers

24,052
citations

17405

63
h-index

7496

151
g-index

184
all docs

184
docs citations

184
times ranked

21346
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 262-272.	3.0	1,824
2	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220.	0.6	1,241
3	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v8-v30.	0.6	1,168
4	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1183-1192.	3.0	1,128
5	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. <i>Lancet</i> , The, 2011, 377, 914-923.	6.3	949
6	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	0.6	891
7	3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017, 28, 16-33.	0.6	865
8	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017, 28, 1700-1712.	0.6	844
9	Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. <i>Clinical Cancer Research</i> , 2007, 13, 3207-3214.	3.2	839
10	Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12%155 patients. <i>British Journal of Cancer</i> , 2007, 96, 1504-1513.	2.9	763
11	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
12	Clinical Application of the 70-Gene Profile: The MINDACT Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 729-735.	0.8	449
13	High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller. <i>Journal of Clinical Oncology</i> , 2009, 27, 5700-5706.	0.8	404
14	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Annals of Oncology</i> , 2014, 25, 1871-1888.	0.6	402
15	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii11-vii19.	0.6	400
16	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi7-vi23.	0.6	400
17	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). <i>European Journal of Cancer</i> , 2017, 75, 284-298.	1.3	363
18	International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 456-463.	3.0	325

#	ARTICLE	IF	CITATIONS
19	Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. <i>Annals of Oncology</i> , 2016, 27, v103-v110.	0.6	292
20	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012, 21, 242-252.	0.9	291
21	Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. <i>Annals of Oncology</i> , 2002, 13, 1036-1043.	0.6	276
22	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014, 23, 489-502.	0.9	269
23	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi25-vi30.	0.6	266
24	The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 295-302.	1.1	260
25	Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. <i>Annals of Oncology</i> , 2005, 16, 1723-1739.	0.6	254
26	Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Annals of Oncology</i> , 2018, 29, 405-417.	0.6	246
27	The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. <i>European Journal of Cancer</i> , 2012, 48, 3355-3377.	1.3	237
28	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 540-551.	4.3	222
29	Male breast cancer: a disease distinct from female breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 37-48.	1.1	205
30	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	0.9	203
31	International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1174-1181.	3.0	202
32	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi12-vi24.	0.6	197
33	BRCA in breast cancer: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2011, 22, vi31-vi34.	0.6	174
34	ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696.	0.6	172
35	3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <i>Breast</i> , 2017, 31, 244-259.	0.9	171
36	Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). <i>Breast</i> , 2018, 39, 131-138.	0.9	167

#	ARTICLE	IF	CITATIONS
37	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2011, 12, 1134-1142.	5.1	165
38	Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer. <i>Oncologist</i> , 2004, 9, 617-632.	1.9	152
39	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). <i>Annals of Oncology</i> , 2015, 26, 873-879.	0.6	151
40	Second international consensus guidelines for breast cancer in young women (BCY2). <i>Breast</i> , 2016, 26, 87-99.	0.9	142
41	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	0.9	135
42	Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. <i>Annals of Oncology</i> , 2002, 13, 197-207.	0.6	128
43	The MINDACT trial: The first prospective clinical validation of a genomic tool. <i>Molecular Oncology</i> , 2007, 1, 246-251.	2.1	117
44	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	0.9	111
45	Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2019, 30, 365-373.	0.6	106
46	Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. <i>Cancer Treatment Reviews</i> , 2017, 53, 98-110.	3.4	101
47	Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. <i>Annals of Oncology</i> , 2003, 14, 1346-1363.	0.6	97
48	Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice. <i>Clinical Cancer Research</i> , 2005, 11, 4393-4399.	3.2	96
49	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v15-v19.	0.6	95
50	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2 ⁺ Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 851-859.	3.2	90
51	Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer. <i>Oncologist</i> , 2007, 12, 253-270.	1.9	85
52	Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1207-14.	1.9	84
53	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)â€™MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013, 22, 203-210.	0.9	77
54	Microtubule-Associated Parameters as Predictive Markers of Docetaxel Activity in Advanced Breast Cancer Patients: Results of a Pilot Study. <i>Clinical Breast Cancer</i> , 2002, 3, 341-345.	1.1	74

#	ARTICLE	IF	CITATIONS
55	Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 5638-5644.	0.8	72
56	Evaluation of HER2, p53, bcl-2, topoisomerase II \pm , heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. <i>Annals of Oncology</i> , 2001, 12, 615-620.	0.6	71
57	Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing. <i>Breast Cancer Research and Treatment</i> , 2002, 74, 113-120.	1.1	69
58	Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv15-iv18.	0.6	69
59	Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. <i>Breast</i> , 2010, 19, 388-395.	0.9	69
60	Breast Cancer Under Age 40: a Different Approach. <i>Current Treatment Options in Oncology</i> , 2015, 16, 16.	1.3	67
61	Squamous cell carcinoma of the breast. <i>Breast</i> , 2000, 9, 315-319.	0.9	66
62	Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. <i>British Journal of Cancer</i> , 2010, 103, 1788-1793.	2.9	64
63	Research needs in breast cancer. <i>Annals of Oncology</i> , 2017, 28, 208-217.	0.6	64
64	Resistance to Trastuzumab: A Necessary Evil or a Temporary Challenge?. <i>Clinical Breast Cancer</i> , 2002, 3, 247-257.	1.1	60
65	Supportive care during treatment for breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. <i>Breast</i> , 2013, 22, 593-605.	0.9	60
66	Time for more optimism in metastatic breast cancer?. <i>Cancer Treatment Reviews</i> , 2014, 40, 220-228.	3.4	59
67	Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2 \pm positive breast cancer cells in a synergistic manner. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3042-3051.	1.9	58
68	European Breast Cancer Conference \hat{A} manifesto on breast centres/units. <i>European Journal of Cancer</i> , 2017, 72, 244-250.	1.3	58
69	Stemming Resistance to HER-2 Targeted Therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2009, 14, 55-66.	1.0	57
70	Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 221-226.	1.1	55
71	Predicting Anthracycline Benefit: <i>TOP2A</i> and CEP17 \hat{A} Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015, 33, 1680-1687.	0.8	55
72	An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. <i>Annals of Oncology</i> , 2020, 31, 283-288.	0.6	54

#	ARTICLE	IF	CITATIONS
73	Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2009, 9, 148-162.	0.8	53
74	Mammographic screening detects low-risk tumor biology breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 103-111.	1.1	53
75	Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Pre-Genomic Era. <i>Oncologist</i> , 2006, 11, 111-125.	1.9	52
76	Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys. <i>Breast</i> , 2016, 28, 5-12.	0.9	51
77	Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 123-131.	1.1	51
78	Individualization of therapy using Mammaprint: from development to the MINDACT Trial. <i>Cancer Genomics and Proteomics</i> , 2007, 4, 147-55.	1.0	51
79	p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. <i>Annals of Oncology</i> , 2007, 18, 997-1003.	0.6	50
80	High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467). <i>Oncology</i> , 2014, 25, 816-823.	0.6	50
81	Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 92, 887-895.	0.6	49
82	Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 977.	3.4	48
83	A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. <i>Cancer Treatment Reviews</i> , 2013, 39, 457-465.	3.4	47
84	Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4-9 positive lymph nodes. <i>Breast</i> , 2013, 22, 682-690.	0.9	47
85	Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. <i>Annals of Oncology</i> , 2003, 14, 693-698.	0.6	44
86	Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. <i>British Journal of Cancer</i> , 2008, 98, 1500-1507.	2.9	43
87	Targeting the Ubiquitin-Proteasome Pathway in Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 148-157.	1.1	40
88	Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014. <i>Lancet Oncology</i> , The, 2015, 16, e137-e147.	5.1	37
89	Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy. <i>Communications Biology</i> , 2020, 3, 299.	2.0	37
90	Bringing Molecular Prognosis and Prediction to the Clinic. <i>Clinical Breast Cancer</i> , 2005, 6, 61-76.	1.1	36

#	ARTICLE	IF	CITATIONS
91	Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. <i>European Journal of Cancer</i> , 2009, 45, 1201-1208.	1.3	36
92	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 125, 69-82.	1.3	36
93	Molecular profiling of head and neck tumors. <i>Current Opinion in Oncology</i> , 2004, 16, 211-214.	1.1	35
94	Breast cancer surgery with augmented reality. <i>Breast</i> , 2021, 56, 14-17.	0.9	34
95	Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. <i>Annals of Oncology</i> , 2003, 14, 1419-1424.	0.6	33
96	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	0.9	31
97	Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II- α gene amplification and protein overexpression in locally advanced/metastatic breast cancer. <i>International Journal of Oncology</i> , 2004, 24, 201.	1.4	30
98	HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. <i>Annals of Oncology</i> , 2008, 19, 223-232.	0.6	30
99	Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012, 21, 20-26.	0.9	30
100	Comparison of Topoisomerase-II α Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites. <i>Breast Cancer Research and Treatment</i> , 2003, 77, 199-204.	1.1	29
101	Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. <i>International Journal of Oncology</i> , 2004, 24, 201-9.	1.4	29
102	Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 272-279.	12.5	28
103	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1335-1345.	0.8	28
104	Chemoprevention for breast cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 329-339.	3.4	26
105	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458.	0.8	25
106	Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma. <i>Annals of Oncology</i> , 2001, 12, 1757-1759.	0.6	24
107	Review on the clinical use of eribulin mesylate for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 589-600.	0.9	24
108	Use and abuse of taxanes in the management of metastatic breast cancer. <i>European Journal of Cancer</i> , 2003, 39, 1978-1989.	1.3	22

#	ARTICLE	IF	CITATIONS
109	Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. <i>Oncology Reports</i> , 2004, 12, 701-7.	1.2	22
110	Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. <i>Annals of Oncology</i> , 2013, 24, 2985-2989.	0.6	22
111	Targeting CDK4/6 pathways and beyond in breast cancer. <i>Breast</i> , 2019, 43, 8-17.	0.9	22
112	An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. <i>Breast</i> , 2012, 21, 716-723.	0.9	21
113	Metastatic breast cancer patients: The forgotten heroes!. <i>Breast</i> , 2009, 18, 271-272.	0.9	20
114	Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 463-469.	1.1	19
115	Correlation between topoisomerase-II \pm gene amplification and protein expression in HER-2 amplified breast cancer. <i>International Journal of Oncology</i> , 2004, 25, 1473-9.	1.4	18
116	Facts and controversies in the use of trastuzumab in the adjuvant setting. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 645-654.	4.3	18
117	PARP inhibitors coming of age. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 69-70.	12.5	18
118	Why is appropriate healthcare inaccessible for many European breast cancer patients? â€œ The EBCC 12 manifesto. <i>Breast</i> , 2021, 55, 128-135.	0.9	18
119	Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. <i>Anticancer Research</i> , 2001, 21, 789-95.	0.5	18
120	Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. <i>British Journal of Cancer</i> , 2012, 106, 1618-1625.	2.9	17
121	Challenges in breast cancer clinical trial design in the postgenomic era. <i>Current Opinion in Oncology</i> , 2004, 16, 536-541.	1.1	16
122	Gaps in Care and Support for Patients With Advanced Breast Cancer: A Report From the Advanced Breast Cancer Global Alliance. <i>JCO Global Oncology</i> , 2021, 7, 976-984.	0.8	16
123	New data on chemotherapy in the adjuvant setting. <i>Breast</i> , 2003, 12, 373-378.	0.9	15
124	Use of trastuzumab for the treatment of early stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1153-1164.	1.1	13
125	Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature. <i>European Journal of Cancer</i> , 2014, 50, 1045-1054.	1.3	13
126	An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint $\hat{\text{A}}^{\text{®}}$). <i>European Journal of Cancer</i> , 2017, 75, 5-13.	1.3	13

#	ARTICLE	IF	CITATIONS
127	Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. <i>Annals of Oncology</i> , 2021, 32, 1077-1082.	0.6	13
128	Potential Predictive Value of Bcl-2 for Response to Tamoxifen in the Adjuvant Setting of Node-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 364-369.	1.1	12
129	Small breast cancers: When and how to treat. <i>Cancer Treatment Reviews</i> , 2014, 40, 1129-1136.	3.4	12
130	A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053) Tj ETQq0 0 0 rgBT /Overlock 10	0.9	12
131	Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. <i>International Journal of Clinical Oncology</i> , 2002, 7, 245-253.	1.0	11
132	The best use of chemotherapy in the adjuvant setting. <i>Breast</i> , 2003, 12, 522-528.	0.9	11
133	The pipeline of new anticancer agents for breast cancer treatment in 2003. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 45-63.	2.0	11
134	Progress in systemic therapy for breast cancer: an overview and perspectives. <i>European Journal of Cancer, Supplement</i> , 2003, 1, 56-69.	2.2	11
135	3D digital breast cancer models with multimodal fusion algorithms. <i>Breast</i> , 2020, 49, 281-290.	0.9	11
136	CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer. <i>Breast</i> , 2021, 55, 75-78.	0.9	11
137	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016, 6, S1-S10.	0.4	10
138	Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. <i>Journal of Clinical Oncology</i> , 2008, 26, 1057-1057.	0.8	10
139	MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 193-205.	1.6	9
140	Challenges in optimizing care in advanced breast cancer patients: Results of an international survey linked to the ABC1 consensus conference. <i>Breast</i> , 2015, 24, 623-629.	0.9	8
141	Anthracyclines in the treatment of early breast cancer friend or foe?. <i>Breast</i> , 2022, 65, 67-76.	0.9	8
142	Optimizing Anthracycline Therapy for Node Positive Breast Cancer. <i>American Journal of Cancer</i> , 2002, 1, 257-268.	0.4	7
143	Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. <i>Communications Biology</i> , 2020, 3, 397.	2.0	7
144	Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. <i>Breast</i> , 2021, 55, 79-90.	0.9	7

#	ARTICLE	IF	CITATIONS
145	A multi-stakeholder approach in optimising patients'™ needs in the benefit assessment process of new metastatic breast cancer treatments. <i>Breast</i> , 2020, 52, 78-87.	0.9	7
146	Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. <i>Cancer Treatment Reviews</i> , 2002, 28, 275-290.	3.4	6
147	Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. <i>Genomics Data</i> , 2013, 1, 7-10.	1.3	6
148	Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 3-22.	2.2	6
149	The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. <i>Annals of Oncology</i> , 2002, 13, 416-421.	0.6	5
150	Perceptions and needs of women with metastatic breast cancer: A focus on clinical trials. <i>Breast</i> , 2013, 22, 370-373.	0.9	5
151	Editorial: Why are guidelines not followed in clinical practice?. <i>Breast</i> , 2017, 32, 245-246.	0.9	5
152	Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 399-410.	1.1	5
153	Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?. <i>Anti-Cancer Drugs</i> , 2003, 14, 703-713.	0.7	4
154	444 The EORTC 10041/BIG 03'04 MINDACT trial is feasible: first results of the pilot phase. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 188.	2.2	4
155	The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 27-33.	2.2	4
156	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
157	Quality-of-life methodology in hormone receptor'positive advanced breast cancer: Current tools and perspectives for the future. <i>Cancer Treatment Reviews</i> , 2022, 102, 102321.	3.4	4
158	Non-endocrine systemic therapies in advanced breast cancer. <i>European Journal of Cancer, Supplement</i> , 2003, 1, 287-298.	2.2	3
159	AUTOIMMUNE HAEMOLYTIC ANAEMIA IN A PATIENT TREATED WITH CAPECITABINE. <i>Acta Clinica Belgica</i> , 2013, 68, 135-137.	0.5	3
160	A call back to reality!. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 67-68.	12.5	3
161	Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 9504-9504.	0.8	3
162	E1. Tailored systemic treatment for breast cancer: dream or reality?. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 2-5.	2.2	2

#	ARTICLE	IF	CITATIONS
163	Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself. International Journal of Gynecological Cancer, 2006, 16, 533-537.	1.2	2
164	Neoadjuvant endocrine therapy: for whom, for how long?. Clinical and Translational Oncology, 2012, 14, 81-82.	1.2	2
165	Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. Journal of Clinical Oncology, 2004, 22, 9504-9504.	0.8	2
166	Putting words into practice. Breast, 2020, 49, 171-173.	0.9	1
167	Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria. Annals of Oncology, 2021, 32, 950-953.	0.6	1
168	Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial). , 2016, , .		1
169	Breast Cancer in Young Women – a Clinical Challenge to Be Addressed in a Multidisciplinary Setting. Breast Care, 2012, 7, 193-194.	0.8	1
170	Regularization Techniques in Radiomics: A Case Study on the Prediction of pCR in Breast Tumours and the Axilla. Lecture Notes in Computer Science, 2020, , 271-281.	1.0	1
171	Vision and collaboration: essential ingredients for the future of breast cancer research. Current Opinion in Oncology, 2004, 16, 521-522.	1.1	0
172	Adjuvant Systemic Therapy, Quo Vadis? Patient Selection, Prognostic and Predictive Factors. Breast Care, 2008, 3, 392-394.	0.8	0
173	Adjuvant Chemotherapy of Breast Cancer. Breast Care, 2009, 4, 9-9.	0.8	0
174	Reply to “Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease” by U. Gueth et al. Annals of Oncology, 2013, 24, 557.	0.6	0
175	Reply to letter from Suguatti et al.. European Journal of Cancer, 2017, 87, 201-202.	1.3	0
176	New strategies for the precision treatment of HER2-driven tumours. Expert Review of Precision Medicine and Drug Development, 2019, 4, 239-249.	0.4	0